Thayer Partners’s Immuneering IMRX Stock Holding History

Thayer Partners’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$53.7K	Hold	11,000	–	–	0.03%	94
2025 Q4	$72.4K	Buy	+11,000	New	+$70.6K	0.04%	90

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Thayer Partners's IMRX Position: Q1 2026 in Review

Thayer Partners held its Immuneering (IMRX) position steady in Q1 2026 at 11,000 shares worth $53.7K. The position accounts for 0.03% of the portfolio, ranked #94.

Thayer Partners first reported a position in IMRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $72.4K in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

Thayer Partners held 11,000 shares of Immuneering worth $53.7K as of Q1 2026.
Thayer Partners left its Immuneering share count unchanged in Q1 2026.
Immuneering made up 0.03% of Thayer Partners's portfolio in Q1 2026, its #94 holding.
Thayer Partners first reported a position in Immuneering in Q4 2025 and has held it in 2 quarters since.
Thayer Partners's Immuneering position peaked at $72.4K in Q4 2025.
95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Thayer Partners's 13F filing for Q1 2026, filed 5 May 2026.